계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Neukio Biotherapeutics
company
About
Neukio Biotherapeutics is a developer of allogenic immune cell therapies for treatment of cancer.
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $50M
- Industries
- Biotechnology
- Founded date
- Jan 1, 2021
- Operating Status
- Active
Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$90M
Neukio Biotherapeutics has raised a total of
$90M
in funding over 2 rounds. Their latest funding was raised on
Sep 2, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 2, 2022 | Series A | $50M | 3 | — | — | Detail |
| Jul 29, 2021 | Angel | $40M | 1 |
Lilly Asia Ventures
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
3
Neukio Biotherapeutics is funded by 3 investors.
Yahui Precision Medicine Fund
and Kuanyu Private Equity
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Yahui Precision Medicine Fund
|
— | Series A |
Kuanyu Private Equity
|
— | Series A |
|
Lilly Asia Ventures
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
